Research articles

Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections

Microbes and Infection
Volume 17, Issue 2, February 2015, Pages 142-148

Tianlei Ying, Haoyang Li, Lu Lu, Dimiter S. Dimitrov, Shibo Jiang

Abstract

The recent Middle East respiratory syndrome coronavirus (MERS-CoV) outbreak poses a serious threat to public health. Here, we summarize recent advances in identifying human neutralizing monoclonal antibodies (mAbs) against MERS-CoV, describe their mechanisms of action, and analyze their potential for treatment of MERS-CoV infections.

Keywords

Coronavirus, MERS-CoV, mAbs, Receptor binding domain (RBD)

Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein

Virus Research
Volume 194, 19 December 2014, Pages 200-210

Shuai Xia, Qi Liu, Qian Wang, Zhiwu Sun, Shan Su, Lanying Du, Tianlei Ying, Lu Lu, Shibo Jiang

Abstract

The recent outbreak of Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV) infection has led to more than 800 laboratory-confirmed MERS cases with a high case fatality rate (∼35%), posing a serious threat to global public health and calling for the development of effective and safe therapeutic and prophylactic strategies to treat and prevent MERS-CoV infection. Here we discuss the most recent studies on the structure of the MERS-CoV spike protein and its role in virus binding and entry, and the development of MERS-CoV entry/fusion inhibitors targeting the S1 subunit, particularly the receptor-binding domain (RBD), and the S2 subunit, especially the HR1 region, of the MERS-CoV spike protein. We then look ahead to future applications of these viral entry/fusion inhibitors, either alone or in combination with specific and nonspecific MERS-CoV replication inhibitors, for the treatment and prevention of MERS-CoV infection.

Keywords

Middle East respiratory syndrome coronavirus, MERS-CoV, Receptor-binding domain, Fusion inhibitor, Entry inhibitor, Six-helix bundle

Coronavirus virulence genes with main focus on SARS-CoV envelope gene

Virus Research
Volume 194, 19 December 2014, Pages 124-137

Marta L. DeDiego, Jose L. Nieto-Torres, Jose M. Jimenez-Guardeño, Jose A. Regla-Nava, Carlos Castaño-Rodriguez, Raul Fernandez-Delgado, Fernando Usera, Luis Enjuanes

Abstract

Coronavirus (CoV) infection is usually detected by cellular sensors, which trigger the activation of the innate immune system. Nevertheless, CoVs have evolved viral proteins that target different signaling pathways to counteract innate immune responses. Some CoV proteins act as antagonists of interferon (IFN) by inhibiting IFN production or signaling, aspects that are briefly addressed in this review. After CoV infection, potent cytokines relevant in controlling virus infections and priming adaptive immune responses are also generated. However, an uncontrolled induction of these proinflammatory cytokines can lead to pathogenesis and disease severity as described for SARS-CoV and MERS-CoV. The cellular pathways mediated by interferon regulatory factor (IRF)-3 and -7, activating transcription factor (ATF)-2/jun, activator protein (AP)-1, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), and nuclear factor of activated T cells (NF-AT), are the main drivers of the inflammatory response triggered after viral infections, with NF-κB pathway the most frequently activated. Key CoV proteins involved in the regulation of these pathways and the proinflammatory immune response are revisited in this manuscript.

It has been shown that the envelope (E) protein plays a variable role in CoV morphogenesis, depending on the CoV genus, being absolutely essential in some cases (genus α CoVs such as TGEV, and genus β CoVs such as MERS-CoV), but not in others (genus β CoVs such as MHV or SARS-CoV). A comprehensive accumulation of data has shown that the relatively small E protein elicits a strong influence on the interaction of SARS-CoV with the host. In fact, after infection with viruses in which this protein has been deleted, increased cellular stress and unfolded protein responses, apoptosis, and augmented host immune responses were observed. In contrast, the presence of E protein activated a pathogenic inflammatory response that may cause death in animal models and in humans.

The modification or deletion of different motifs within E protein, including the transmembrane domain that harbors an ion channel activity, small sequences within the middle region of the carboxy-terminus of E protein, and its most carboxy-terminal end, which contains a PDZ domain-binding motif (PBM), is sufficient to attenuate the virus. Interestingly, a comprehensive collection of SARS-CoVs in which these motifs have been modified elicited full and long-term protection even in old mice, making those deletion mutants promising vaccine candidates. These data indicate that despite its small size, E protein drastically influences the replication of CoVs and their pathogenicity. Although E protein is not essential for CoV genome replication or subgenomic mRNA synthesis, it affects virus morphogenesis, budding, assembly, intracellular trafficking, and virulence. In fact, E protein is responsible in a significant proportion of the inflammasome activation and the associated inflammation elicited by SARS-CoV in the lung parenchyma. This exacerbated inflammation causes edema accumulation leading to acute respiratory distress syndrome (ARDS) and, frequently, to the death of infected animal models or human patients.

Keywords

Coronavirus, SARS-CoV, MERS-CoV, Innate immunity, Inflammation, Envelope protein



Travel implications of emerging coronaviruses: SARS and MERS-CoV

Travel Medicine and Infectious Disease
Volume 12, Issue 5, September–October 2014, Pages 422-428

Jaffar A. Al-Tawfiq Alimuddin Zumla, Ziad A. Memish

Abstract

The emergence of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and of the Middle East Syndrome Cornavirus (MERS-CoV) caused widespread fear and concern for their potential threat to global health security. There are similarities and differences in the epidemiology and clinical features between these two diseases. The origin of SARS-COV and MERS-CoV is thought to be an animal source with subsequent transmission to humans. The identification of both the intermediate host and the exact route of transmission of MERS-CoV is crucial for the subsequent prevention of the introduction of the virus into the human population. So far MERS-CoV had resulted in a limited travel-associated human cases with no major events related to the Hajj.

Keywords

MERS-CoV, SARS-CoV, Hajj: zoonosis, Travel


The replication of a mouse adapted SARS-CoV in a mouse cell line stably expressing the murine SARS-CoV receptor mACE2 efficiently induces the expression of proinflammatory cytokines

Journal of Virological Methods
Volume 193, Issue 2, November 2013, Pages 639-646

Jose A. Regla-Nava, Jose M. Jimenez-Guardeño, Jose L. Nieto- Torres, Thomas M. Gallagher, Luis Enjuanes, Marta L. DeDiego

Abstract

Infection of conventional mice with a mouse adapted (MA15) severe acute respiratory syndrome (SARS) coronavirus (CoV) reproduces many aspects of human SARS such as pathological changes in lung, viremia, neutrophilia, and lethality. However, established mouse cell lines highly susceptible to mouse-adapted SARS-CoV infection are not available. In this work, efficiently transfectable mouse cell lines stably expressing the murine SARS-CoV receptor angiotensin converting enzyme 2 (ACE2) have been generated. These cells yielded high SARS-CoV-MA15 titers and also served as excellent tools for plaque assays. In addition, in these cell lines, SARS-CoV-MA15 induced the expression of proinflammatory cytokines and IFN-β, mimicking what has been observed in experimental animal models infected with SARS-CoV and SARS patients. These cell lines are valuable tools to perform in vitro studies in a mouse cell system that reflects the species used for in vivo studies of SARS-CoV-MA15 pathogenesis.

Keywords

SARS, Coronavirus, Mouse adapted, Stably transformed murine cells, SARS-CoV receptor ACE2, Proinflammatory cytokines



Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) – possible lessons from a systematic review of SARS-CoV therapy

International Journal of Infectious Diseases
Volume 17, Issue 10, October 2013, Pages e792-e798

Hisham Momattin, Khurram Mohammed, Alimuddin Zumla, Ziad A. Memish, Jaffar A. Al-Tawfiq

Abstract

The Middle East Respiratory Syndrome coronavirus (MERS-CoV) has been detected in a number of countries in the Middle East and Europe with an apparently high mortality rate. It is phylogenetically related to the SARS coronavirus and has also been associated with severe respiratory illness as well as nosocomial transmission in healthcare settings. Current international recommendations do not support any specific therapies; however, there are a number of agents, which were used during the SARS epidemic of 2003. It is possible that these might be active against the related MERS coronavirus. We have reviewed the literature on the safety and efficacy of therapies used in patients with SARS with a view to their potential use in patients with MERS-CoV infections.

Keywords

MERS-CoV, Interferon, Ribavarin, SARS

Dieckol, a SARS-CoV 3CLpro inhibitor, isolated from the edible brown algae Ecklonia cava

Bioorganic & Medicinal Chemistry
Volume 21, Issue 13, 1 July 2013, Pages 3730-3737

Ji-Young Park, Jang Hoon Kim, Jung Min Kwon, Hyung- Jun Kwon, Hyung Jae Jeong, Young Min Kim, Doman Kim, Woo Song Lee, Young Bae Ryu

Abstract

SARS-CoV 3CLpro plays an important role in viral replication. In this study, we performed a biological evaluation on nine phlorotannins isolated from the edible brown algae Ecklonia cava. The nine isolated phlorotannins (19), except phloroglucinol (1), possessed SARS-CoV 3CLpro inhibitory activities in a dose-dependently and competitive manner. Of these phlorotannins (19), two eckol groups with a diphenyl ether linked dieckol (8) showed the most potent SARS-CoV 3CLpro trans/cis-cleavage inhibitory effects (IC50s = 2.7 and 68.1 μM, respectively). This is the first report of a (8) phlorotannin chemotype significantly blocking the cleavage of SARS-CoV 3CLpro in a cell-based assay with no toxicity. Furthermore, dieckol (8) exhibited a high association rate in the SPR sensorgram and formed extremely strong hydrogen bonds to the catalytic dyad (Cys145 and His41) of the SARS-CoV 3CLpro.

Keywords

Phlorotannin, SARS-CoV, Dieckol, Eckol, Ecklonia cava



Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases

Bioorganic & Medicinal Chemistry
Volume 20, Issue 19, 1 October 2012, Pages 5928-5935

Ji-Young Park, Jang Hoon Kim, Young Min Kim, Hyung Jae Jeong, Dae Wook Kim, Ki Hun Park, Hyung-Jun Kwon, Su-Jin Park, Woo Song Lee, Young Bae Ryu

Abstract

In the search for anti-SARS-CoV, tanshinones derived from Salvia miltiorrhiza were found to be specific and selective inhibitors for the SARS-CoV 3CLpro and PLpro, viral cysteine proteases. A literature search for studies involving the seven isolated tanshinone hits showed that at present, none have been identified as coronaviral protease inhibitors. We have identified that all of the isolated tanshinones are good inhibitors of both cysteine proteases. However, their activity was slightly affected by subtle changes in structure and targeting enzymes. All isolated compounds (17) act as time dependent inhibitors of PLpro, but no improved inhibition was observed following preincubation with the 3CLpro. In a detail kinetic mechanism study, all of the tanshinones except rosmariquinone (7) were identified as noncompetitive enzyme isomerization inhibitors. However, rosmariquinone (7) showed a different kinetic mechanism through mixed-type simple reversible slow-binding inhibition. Furthermore, tanshinone I (5) exhibited the most potent nanomolar level inhibitory activity toward deubiquitinating (IC50 = 0.7 μM). Additionally, the inhibition is selective because these compounds do not exert significant inhibitory effects against other proteases including chymotrysin, papain, and HIV protease. These findings provide potential inhibitors for SARS-CoV viral infection and replication.

Keywords

Tanshinone, SARS-CoV, 3CLpro, PLpro, Slow-binding inhibitor


Identification of myricetin and scutellarein as novel chemical inhibitors of the SARS coronavirus helicase, nsP13

Bioorganic & Medicinal Chemistry Letters
Volume 22, Issue 12, 15 June 2012, Pages 4049-4054

Mi-SunYu, June Leeb, Jin Moo Lee, Younggyu KimcYoung-WonChin, Jun-GooJeee, Young-Sam Keum, Yong-Joo Jeong

Abstract

Severe acute respiratory syndrome (SARS) is an infectious disease with a strong potential for transmission upon close personal contact and is caused by the SARS-coronavirus (CoV). However, there are no natural or synthetic compounds currently available that can inhibit SARS-CoV. We examined the inhibitory effects of 64 purified natural compounds against the activity of SARS helicase, nsP13, and the hepatitis C virus (HCV) helicase, NS3h, by conducting fluorescence resonance energy transfer (FRET)-based double-strand (ds) DNA unwinding assay or by using a colorimetry-based ATP hydrolysis assay. While none of the compounds, examined in our study inhibited the DNA unwinding activity or ATPase activity of human HCV helicase protein, we found that myricetin and scutellarein potently inhibit the SARS-CoV helicase protein in vitro by affecting the ATPase activity, but not the unwinding activity, nsP13. In addition, we observed that myricetin and scutellarein did not exhibit cytotoxicity against normal breast epithelial MCF10A cells. Our study demonstrates for the first time that selected naturally-occurring flavonoids, including myricetin and scultellarein might serve as SARS-CoV chemical inhibitors.

Keywords

Myricetin, Scutellarein, SARS-coronavirus (SARS-CoV) helicase

Diagnostics of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid antigen using chicken immunoglobulin Y

Poultry Science
Volume 91, Issue 3, 1 March 2012, Pages 636-642

A .Palaniyappan, D. Das, S. Kammila, M.R. Suresh, H.H. Sunwoo

Abstract

The goal of this study was to develop a quantitative detection system for severe acute respiratory syndrome-associated coronavirus (SARS-CoV), targeting the nucleocapsid protein (NP), to determine the presence and degree of infection in suspected individuals. Because the NP is the viral protein shed during infection and its template mRNA is the most abundant subgenomic RNA, it is a suitable candidate for developing antibodies for diagnostic applications. In this study, we have prepared full-length SARS-CoV NP expressed in Escherichia coli and purified. Full-length NP was used for the preparation of mouse monoclonal antibody and chicken polyclonal IgY antibodies for the development of heterosandwich ELISA for early diagnostics of SARS-suspected individuals. The sensitivity of the developed heterosandwich ELISA can detect the viral antigen at 18.5 pg/mL of recombinant NP. This study describes ultrasensitive ELISA using 19B6 monoclonal antibody as the capture antibody and IgY as the detecting antibody against the most abundant SARS-CoV NP antigens. One of the most important findings was the use of inexpensive polyclonal IgY antibody to increase the sensitivity of the detection system for SARS-CoV at the picogram level. Furthermore, the immunoassay of SARS-CoV NP antigen developed could be an effective and sensitive method of diagnosing SARS-suspected individuals during a future SARS-CoV outbreak.

Key words

SARS-CoV, nucleocapsid protein, 19B6 monoclonal antibody, immunoglobulin Y, heterosandwich ELISA



Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506

Virus Research
Volume 165, Issue 1, April 2012, Pages 112-117

Javier Carbajo-Lozoya, Marcel A.Müller, Stephan Kallies, Volker Thiel, Christian Drosten, Albrechtvon Brunn

Abstract

Recent research has shown that Coronavirus (CoV) replication depends on active immunophilin pathways. Here we demonstrate that the drug FK506 (Tacrolimus) inhibited strongly the growth of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E at low, non-cytotoxic concentrations in cell culture. As shown by plaque titration, qPCR, Luciferase- and green fluorescent protein (GFP) reporter gene expression, replication was diminished by several orders of magnitude. Knockdown of the cellular FK506-binding proteins FKBP1A and FKBP1B in CaCo2 cells prevented replication of HCoV-NL63, suggesting the requirement of these members of the immunophilin family for virus growth.

Keywords

SARS-CoV, HCoV-NL63, HCoV-229E, FK506, Tacrolimus, Immunophilins, FKBP1A (FKBP12), FKBP1B, (FKBP12.6), Inhibition of viral replication

A hexapeptide of the receptor-binding domain of SARS corona virus spike protein blocks viral entry into host cells via the human receptor ACE2

Antiviral Research
Volume 94, Issue 3, June 2012, Pages 288-296

Anna-WinonaStruck, Marco Axmanna, Susanne Pfefferle, ChristianDrosten, Bernd Meyera

Abstract

In vitro infection of Vero E6 cells by SARS coronavirus (SARS-CoV) is blocked by hexapeptide Tyr-Lys-Tyr-Arg-Tyr-Leu. The peptide also inhibits proliferation of coronavirus NL63. On human cells both viruses utilize angiotensin-converting enzyme 2 (ACE2) as entry receptor. Blocking the viral entry is specific as alpha virus Sindbis shows no reduction in infectivity. Peptide 438YKYRYL443 is part of the receptor-binding domain (RBD) of the spike protein of SARS-CoV. Peptide libraries were screened by surface plasmon resonance (SPR) to identify RBD binding epitopes. 438YKYRYL443 carries the dominant binding epitope and binds to ACE2 with KD = 46 μM. The binding mode was further characterized by saturation transfer difference (STD) NMR spectroscopy and molecular dynamic simulations. Based on this information the peptide can be used as lead structure to design potential entry inhibitors against SARS-CoV and related viruses.

Keywords

SARS coronavirus, Spike protein, ACE2, Entry inhibitor, Virus proliferation assay, SPR screening

Diagnostics of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) nucleocapsid antigen using chicken immunoglobulin Y

Poultry Science
Volume 91, Issue 3, 1 March 2012, Pages 636-642

A. Palaniyappan, D.Das, S.Kammila, M.R.Suresh, H.H.Sunwoo

Abstract

The goal of this study was to develop a quantitative detection system for severe acute respiratory syndrome-associated coronavirus (SARS-CoV), targeting the nucleocapsid protein (NP), to determine the presence and degree of infection in suspected individuals. Because the NP is the viral protein shed during infection and its template mRNA is the most abundant subgenomic RNA, it is a suitable candidate for developing antibodies for diagnostic applications. In this study, we have prepared full-length SARS-CoV NP expressed in Escherichia coli and purified. Full-length NP was used for the preparation of mouse monoclonal antibody and chicken polyclonal IgY antibodies for the development of heterosandwich ELISA for early diagnostics of SARS-suspected individuals. The sensitivity of the developed heterosandwich ELISA can detect the viral antigen at 18.5 pg/mL of recombinant NP. This study describes ultrasensitive ELISA using 19B6 monoclonal antibody as the capture antibody and IgY as the detecting antibody against the most abundant SARS-CoV NP antigens. One of the most important findings was the use of inexpensive polyclonal IgY antibody to increase the sensitivity of the detection system for SARS-CoV at the picogram level. Furthermore, the immunoassay of SARS-CoV NP antigen developed could be an effective and sensitive method of diagnosing SARS-suspected individuals during a future SARS-CoV outbreak.

Key words

SARS-CoV nucleocapsid protein, 19B6 monoclonal antibody, immunoglobulin Y, heterosandwich ELISA

Inhibitors of SARS-CoV entry – Identification using an internally-controlled dual envelope pseudovirion assay

Antiviral Research
Volume 92, Issue 2, November 2011, Pages 187-194

Yanchen Zhou, Juliet Agudelo, KaiLu, David H.Goetz Elizabeth Hansell, Yen Ting Chen William R.Roush, James McKerrow, Charles S.Craik, Sean M.Amberg, Graham Simmons

Abstract

Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) emerged as the causal agent of an endemic atypical pneumonia, infecting thousands of people worldwide. Although a number of promising potential vaccines and therapeutic agents for SARS-CoV have been described, no effective antiviral drug against SARS-CoV is currently available. The intricate, sequential nature of the viral entry process provides multiple valid targets for drug development. Here, we describe a rapid and safe cell-based high-throughput screening system, dual envelope pseudovirion (DEP) assay, for specifically screening inhibitors of viral entry. The assay system employs a novel dual envelope strategy, using lentiviral pseudovirions as targets whose entry is driven by the SARS-CoV Spike glycoprotein. A second, unrelated viral envelope is used as an internal control to reduce the number of false positives. As an example of the power of this assay a class of inhibitors is reported with the potential to inhibit SARS-CoV at two steps of the replication cycle, viral entry and particle assembly. This assay system can be easily adapted to screen entry inhibitors against other viruses with the careful selection of matching partner virus envelopes.

Keywords

Inhibitors of SARS-CoV entry, Antiviral, HTS, High-throughput screening, Dual envelope pseudovirion assay, Pseudovirus

SARS-CoV S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV

Vaccine
Volume 29, Issue 38, 2 September 2011, Pages 6606-6613

Ye V. Liu, Michael J. Massare, Dale L.Barnard, Thomas Kort, Margret Nathana, Lei Wang, Gale Smith

Abstract

SARS-CoV was the cause of the global pandemic in 2003 that infected over 8000 people in 8 months. Vaccines against SARS are still not available. We developed a novel method to produce high levels of a recombinant SARS virus-like particles (VLPs) vaccine containing the SARS spike (S) protein and the influenza M1 protein using the baculovirus insect cell expression system. These chimeric SARS VLPs have a similar size and morphology to the wild type SARS-CoV. We tested the immunogenicity and protective efficacy of purified chimeric SARS VLPs and full length SARS S protein vaccines in a mouse lethal challenge model. The SARS VLP vaccine, containing 0.8 μg of SARS S protein, completely protected mice from death when administered intramuscular (IM) or intranasal (IN) routes in the absence of an adjuvant. Likewise, the SARS VLP vaccine, containing 4 μg of S protein without adjuvant, reduced lung virus titer to below detectable level, protected mice from weight loss, and elicited a high level of neutralizing antibodies against SARS-CoV. Sf9 cell-produced full length purified SARS S protein was also an effective vaccine against SARS-CoV but only when co-administered IM with aluminum hydroxide. SARS-CoV VLPs are highly immunogenic and induce neutralizing antibodies and provide protection against lethal challenge. Sf9 cell-based VLP vaccines are a potential tool to provide protection against novel pandemic agents.

Keywords

Severe acute respiratory syndrome, Virus like particles, Lung virus titer, Neutralizing antibody, Baculovirus, Influenza

The immune responses of HLA-A*0201 restricted SARS-CoV S peptide-specific CD8+ T cells are augmented in varying degrees by CpG ODN, PolyI:C and R848

Vaccine
Volume 29, Issue 38, 2 September 2011, Pages 6670-6678

Kai Zhao, Hui Wang Chang youWu

Abstract

The induction of antigen specific memory CD8+ T cells in vivo is very important to new vaccines against infectious diseases. In the present study, we aimed to evaluate the immune responses of peptide-specific CD8+ T cells induced by HLA-A*0201 restricted severe acute respiratory syndrome-associated coronavirus (SARS-CoV) S epitopes plus CpG oligodeoxynucleotide (CpG ODN), PolyI:C and R848 as adjuvants. Furthermore, the generation, distribution and phenotype of long-lasting peptide-specific memory CD8+ T cells were assessed by ELISA, ELISPOT and flow cytometry. Our results showed that antigen specific CD8+ T cells were elicited by HLA-A*0201 restricted SARS-CoV S epitopes. Furthermore, the frequency of peptide-specific CD8+ T cells was dramatically increased after both prime and boost immunization with peptides plus CpG ODN, whereas slight enhancements were induced following boost vaccination with peptides plus PolyI:C or R848. SARS-CoV S peptide-specific IFN-γ+CD8+ T cells were distributed throughout the lymphoid and non-lymphoid tissues. Results also demonstrated that the HLA-A*0201 restricted peptide-specific CD8+ T cells induced by peptides plus CpG ODN carried a memory cell phenotype with CD45RB+ and CD62L− and possessed long-term survival ability in vivo. Taken together, our results implied that HLA-A*0201 restricted SARS-CoV S epitopes plus CpG ODN might be the superior candidates for SARS vaccine.

Keywords

SARS-CoV, Epitope, Adjuvant, T cell, Vaccine

Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses

Peptides
Volume 32, Issue 7, July 2011, Pages 1518-1525

QiaoliLi, Zhenhuan Zhao Dihan Zhou Yaoqing Chenab WeiHong LuyangCao JingyiYang YanZhang Wei Shi ZhijianCao, YingliangWu HuiminYana WenxinLi

Abstract

Outbreaks of SARS-CoV, influenza A (H5N1, H1N1) and measles viruses in recent years have raised serious concerns about the measures available to control emerging and re-emerging infectious viral diseases. Effective antiviral agents are lacking that specifically target RNA viruses such as measles, SARS-CoV and influenza H5N1 viruses, and available vaccinations have demonstrated variable efficacy. Therefore, the development of novel antiviral agents is needed to close the vaccination gap and silence outbreaks. We previously indentified mucroporin, a cationic host defense peptide from scorpion venom, which can effectively inhibit standard bacteria. The optimized mucroporin-M1 can inhibit gram-positive bacteria at low concentrations and antibiotic-resistant pathogens. In this investigation, we further tested mucroporin and the optimized mucroporin-M1 for their antiviral activity. Surprisingly, we found that the antiviral activities of mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses were notably increased with an EC50 of 7.15 μg/ml (3.52 μM) and a CC50 of 70.46 μg/ml (34.70 μM) against measles virus, an EC50 of 14.46 μg/ml (7.12 μM) against SARS-CoV and an EC50 of 2.10 μg/ml (1.03 μM) against H5N1, while the original peptide mucroporin showed no antiviral activity against any of these three viruses. The inhibition model could be via a direct interaction with the virus envelope, thereby decreasing the infectivity of virus. This report provides evidence that host defense peptides from scorpion venom can be modified for antiviral activity by rational design and represents a practical approach for developing broad-spectrum antiviral agents, especially against RNA viruses.

Keywords

Mucroporin-M1, Scorpion venom, Measles, SARS-CoV, H5N1, Antiviral

Inhibition of severe acute respiratory syndrome coronavirus replication in a lethalSARS-CoV BALB/c mouse model by stinging nettle lectin,Urtica dioicaagglutinin

Antiviral Research
Volume 90, Issue 1, April 2011, Pages 22-32

Yohichi Kumaki, Miles K.Wandersee, Aaron J.Smith, Yanchen Zhou, Graham Simmons, Nathan M.Nelson, Kevin W.Bailey, Zachary G. Vest, Joseph K.-K.Li, Paul Kay-SheungChan, Donald F. Smee, Dale L.Barnarda

Abstract

Urtica dioicaagglutinin (UDA) is a small plant monomeric lectin, 8.7kDa in size, with anN-acetylglucosamine specificity that inhibits viruses fromNidovirales in vitro. In the current study, we firstexamined the efficacy of UDA on the replication of different SARS-CoV strains in Vero 76 cells. UDA inhib-ited virus replication in a dose-dependent manner and reduced virus yields of the Urbani strain by 90% at1.1±0.4g/ml in Vero 76 cells. Then, UDA was tested for efficacy in a lethal SARS-CoV-infected BALB/cmouse model. BALB/c mice were infected with two LD50(575PFU) of virus for 4h before the mice weretreated intraperitoneally with UDA at 20, 10, 5 or 0mg/kg/day for 4 days. Treatment with UDA at 5mg/kgsignificantly protected the mice against a lethal infection with mouse-adapted SARS-CoV (p<0.001), butdid not significantly reduce virus lung titers. All virus-infected mice receiving UDA treatments were alsosignificantlyprotectedagainstweightloss(p<0.001).UDAalsoeffectivelyreducedlungpathologyscores.At day 6 after virus exposure, all groups of mice receiving UDA had much lower lung weights than didthe placebo-treated mice. Thus, our data suggest that UDA treatment of SARS infection in mice leads to asubstantial therapeutic effect that protects mice against death and weight loss. Furthermore, the mode ofaction of UDAin vitrowas further investigated using live SARS-CoV Urbani strain virus and retroviral par-ticles pseudotyped with SARS-CoV spike (S). UDA specifically inhibited the replication of live SARS-CoV orSARS-CoV pseudotyped virus when added just before, but not after, adsorption. These data suggested thatUDA likely inhibits SARS-CoV infection by targeting early stages of the replication cycle, namely, adsorp-tion or penetration. In addition, we demonstrated that UDA neutralizes the virus infectivity, presumablyby binding to the SARS-CoV spike (S) glycoprotein. Finally, the target molecule for the inhibition of virusreplication was partially characterized. When UDA was exposed toN-acetylglucosamine and then UDAwas added to cells just prior to adsorption, UDA did not inhibit the virus infection. These data supportthe conclusion that UDA might bind toN-acetylglucosamine-like residues present on the glycosylatedenvelope glycoproteins, thereby preventing virus attachment to cells.

Keywords:

BALB/c mouse, SARS-CoVUrtica, dioicaagglutinin (UDA)

TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds

Antiviral Research
Volume 85, Issue 3, March 2010, Pages 551-555

Shiori Haga, Noriyo Nagata, Tadashi Okamura, Norio Yamamoto Tetsutaro Sata, Naoki Yamamoto, Takehiko Sasazuki Yukihito Ishizaka

Abstract

Because outbreaks of severe acute respiratory syndrome coronavirus (SARS-CoV) might reemerge, identifying antiviral compounds is of key importance. Previously, we showed that the cellular factor TNF-α converting enzyme (TACE), activated by the spike protein of SARS-CoV (SARS-S protein), was positively involved in viral entry, implying that TACE is a possible target for developing antiviral compounds. To demonstrate this possibility, we here tested the effects of TACE inhibitors on viral entry. In vitro and in vivo data revealed that the TACE inhibitor TAPI-2 attenuated entry of both pseudotyped virus expressing the SARS-S protein in a lentiviral vector backbone and infectious SARS-CoV. TAPI-2 blocked both the SARS-S protein-induced shedding of angiotensin-converting enzyme 2 (ACE2), a receptor of SARS-CoV, and TNF-α production in lung tissues. Since the downregulation of ACE2 by SARS-S protein was proposed as an etiological event in the severe clinical manifestations, our data suggest that TACE antagonists block SARS-CoV infection and also attenuate its severe clinical outcome.

Keywords

SARS-CoV, TACE, ACE2, Shedding

Biflavonoids from Torreya nucifera displaying SARS-CoV 3CLpro inhibition

Bioorganic & Medicinal Chemistry
Volume 18, Issue 22, 15 November 2010, Pages 7940-7947

Young BaeRyua, Hyung JaeJeonga, Jang HoonKim, Young MinKim, Ji-Young ParkaDoman Kim Thi Thanh Hanh Naguyen, Su-JinParkaJong SunChangaKi HunPark, Mun-Chual Rho, Woo Song Lee

Abstract

As part of our search for botanical sources of SARS-CoV 3CLpro inhibitors, we selected Torreya nucifera, which is traditionally used as a medicinal plant in Asia. The ethanol extract of T. nucifera leaves exhibited good SARS-CoV 3CLpro inhibitory activity (62% at 100 μg/mL). Following bioactivity-guided fractionation, eight diterpenoids (1–8) and four biflavonoids (9–12) were isolated and evaluated for SARS-CoV 3CLpro inhibition using fluorescence resonance energy transfer analysis. Of these compounds, the biflavone amentoflavone (9) (IC50 = 8.3 μM) showed most potent 3CLpro inhibitory effect. Three additional authentic flavones (apigenin, luteolin and quercetin) were tested to establish the basic structure–activity relationship of biflavones. Apigenin, luteolin, and quercetin inhibited 3CLpro activity with IC50 values of 280.8, 20.2, and 23.8 μM, respectively. Values of binding energy obtained in a molecular docking study supported the results of enzymatic assays. More potent activity appeared to be associated with the presence of an apigenin moiety at position C-3′ of flavones, as biflavone had an effect on 3CLpro inhibitory activity.

Keywords

SARS-CoV 3CLpro,Torreya nucifera, Biflavonoid, Amentoflavone